Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset

DSpace/Manakin Repository

Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset

Citable link to this page

 

 
Title: Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset
Author: Padi, Sathish K.R.; Luevano, Libia A.; An, Ningfei; Pandey, Ritu; Singh, Neha; Song, Jin H.; Aster, Jon C.; Yu, Xue-Zhong; Mehrotra, Shikhar; Kraft, Andrew S.

Note: Order does not necessarily reflect citation order of authors.

Citation: Padi, Sathish K.R., Libia A. Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H. Song, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra, and Andrew S. Kraft. 2017. “Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.” Oncotarget 8 (18): 30199-30216. doi:10.18632/oncotarget.16320. http://dx.doi.org/10.18632/oncotarget.16320.
Full Text & Related Files:
Abstract: New approaches are needed for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) who fail to achieve remission with chemotherapy. Analysis of the effects of pan-PIM protein kinase inhibitors on human T-ALL cell lines demonstrated that the sensitive cell lines expressed higher PIM1 protein kinase levels, whereas T-ALL cell lines with NOTCH mutations tended to have lower levels of PIM1 kinase and were insensitive to these inhibitors. NOTCH-mutant cells selected for resistance to gamma secretase inhibitors developed elevated PIM1 kinase levels and increased sensitivity to PIM inhibitors. Gene profiling using a publically available T-ALL dataset demonstrated overexpression of PIM1 in the majority of early T-cell precursor (ETP)-ALLs and a small subset of non-ETP ALL. While the PIM inhibitors blocked growth, they also stimulated ERK and STAT5 phosphorylation, demonstrating that activation of additional signaling pathways occurs with PIM inhibitor treatment. To block these pathways, Ponatinib, a broadly active tyrosine kinase inhibitor (TKI) used to treat chronic myelogenous leukemia, was added to this PIM-inhibitor regimen. The combination of Ponatinib with a PIM inhibitor resulted in synergistic T-ALL growth inhibition and marked apoptotic cell death. Treatment of mice engrafted with human T-ALL with these two agents significantly decreased the tumor burden and improved the survival of treated mice. This dual therapy has the potential to be developed as a novel approach to treat T-ALL with high PIM expression.
Published Version: doi:10.18632/oncotarget.16320
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444737/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33490861
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters